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RXRRetinoids have been implicated as pharmacological agents for the prevention and treatment of various
types of cancers, including breast cancers. We analyzed 27 newly synthesized retinoids for their bioac-
tivity on breast, liver, and colon cancer cells. Majority of the retinoids demonstrated selective bioactivity
on breast cancer cells. Retinoid 17 had a significant inhibitory activity (IC50 3.5 lM) only on breast cancer
cells while no growth inhibition observed with liver and colon cancer cells. The breast cancer selective
growth inhibitory action by retinoid 17 was defined as p21-dependent cell death, reminiscent of senes-
cence, which is an indicator of targeted receptor mediated bioactivity. A comparative analysis of retinoid
receptor gene expression levels in different breast cancer cells and IC50 values of 17 indicated the involve-
ment of Retinoid X receptors in the cytotoxic bioactivity of retinoid 17 in the senescence associated cell
death. Furthermore, siRNA knockdown studies with RXRc induced decrease in cell proliferation.
Therefore, we suggest that retinoid derivatives that target RXRc, can be considered for breast cancer
therapies.
 2016 Elsevier Inc. All rights reserved.1. Introduction
Vitamin A and its synthetic and naturally occurring derivatives,
known as retinoids, are essential in embryonic development and in
the maintenance of physiological processes involving vision, meta-
bolism, cellular homeostasis and the growth and differentiation of
many tissues [1–3]. Retinoid signaling also plays an important role
in carcinogenesis in transformed cells [4]. Animal experiments, cel-
lular models and clinical trials have supported the idea of using
retinoids as chemopreventive and chemotherapeutic agents [5].
All-trans-retinoic acid (ATRA), as the most-active metabolite, hasbeen reported to affect diverse biological activities, including
breast cancer [6]. ATRA inhibits cell growth in cancer cells by
blocking the G1 phase of the cell cycle [7,8]. G1 arrest is induced
by the induction of cyclin-dependent kinase (CDK) inhibitors such
as p21 and p16 in the presence of ATRA [9,10]. CDK inhibition by
p21 causes dephosphorylation of the retinoblastoma protein, Rb,
leading to the inhibition of the E2F transcription factor. Conse-
quently, target genes involved in cell cycle progression and cell
proliferation are down-regulated [11]. It has been recently shown
that ATRA induces cellular senescence in HepG2 cells through
p21 and p16, and in MCF7 cells only with p21 activation [12].
Breast cancer is the second most common cancer worldwide
and it affects about one in 10 women [13]. As a consequence of
the aging of world populations, this disease is a major public health
problem. Previously, breast cancer was considered a disease of
women in developed countries only, but incidence and mortality
rates have been increasing in less-developed countries in recent
years [13]. In spite of the many developments in early diagnostic
and therapeutic strategies, breast cancer is still a major obstacle.
It is a heterogeneous disease and is classified into luminal,
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receptor (ER)–positive breast cancer cells produce senescent pro-
geny, and this ability is correlated with ER loss and p21 accumula-
tion [14]. Several studies have shown that retinoic acid (RA)
inhibits cell growth, especially in estrogen-receptor–positive
breast cancer cells, by either apoptosis or cell cycle arrest
[15,16]. Retinoids have been explored as therapeutic and preven-
tive agents in different cancer types [17–19]. In breast cancer, reti-
noids, especially fenretinide (4-HPR), have been investigated as
preventive agents in various clinical trials [20].
Most anti-cancer agents inhibit growth by interfering with sig-
naling pathways in cancer cells, ultimately leading to apoptosis.
Recent studies indicate that drug-dependent senescence is a
promising mechanism that may advance cancer therapy [21,22].
During cellular senescence, cells grow old and die due to aging.
Involving novel chemotherapeutic candidates in reprogramming
cell senescence is an important approach in the realm of cancer
treatment. Normally replicative senescence observed due to telom-
ere shortening during replication whereas the molecular analysis
of senescence in cancer cells demonstrated oncogene-induced
senescence (OIS) and PTEN-loss induced cellular senescence (PICS)
mechanisms [23–25]. Based on these findings and due to the pro-
longed activity of retinoids in the cell, we submit that these com-
pounds be further exploited as senescence-associated anti-
proliferative agents in chemotherapeutic regimes.
In this study, we tested previously synthesized retinoid deriva-
tives [26] for their cytotoxicity in a series of breast cancer cell lines.
We then further studied compound 17, which showed the most
anti-proliferative activity, to identify its mechanism of action at
the molecular level.2. Experimental
2.1. Cell culture
The breast cancer cell lines (Cama-1, T47D, MCF7, BT-474,
MDA-MB-453, BT-20, SK-BR-3, MDA-MB-361, MDA-MB-157,
MDA-MB-231 and MCF-12A) were obtained from ATCC. All breast,
Huh7 liver and HCT116 cells were authenticated by STR analysis
regularly. T47D, BT-474, MCF-7, BT-20, MDA-MB-453, MDA-MB-
231 and Huh7 were grown in Dulbecco’s modified Eagle’s medium
(DMEM). Cama-1 and MDA-MB-157 were cultivated in DMEM sup-
plemented with 1% sodium pyruvate. SK-BR-3 was cultivated in
RPMI (glucose rich; 4.5 g/L) medium (Sigma). Unless indicated all
media had phenol red and supplemented with 10% FCS and
50 mg/ml penicillin–streptomycin for both retinoid treated and
control experiments. Compound 17 was further tested in phenol
red free medium in order to validate its cytotoxic activity in
T47D cells. This study does not involve animals or human volun-
teers therefore ethics approval is not required.2.2. Preparation of the compounds
Retinoids were kept in powder form at dark 4 C and they were
dissolved in Dimethyl sulfoxide (DMSO) with a concentration of
20 mM the stock solution of the compounds were prepared and
kept in 20 C during the experiments. For SRB assay concentra-
tion curve from 40 lM, 20 lM, 10 lM, 5 lM to 2.5 lM were used.
For other experiments the concentrations were used as indicated
in the figure legends. The retionids were prepared from the stock
solutions prior to the experiments. Because retionids are light sen-
sitive, compounds were always kept in dark and experiments were
done under dim light.2.3. Sulforhodamine B (SRB) cytotoxicity assay
Retinoids were tested with an National Cancer Institute (NCI)
anticancer drug screening method for their growth-inhibitory
activity [27]. The cells (10,000 cells/well) were seeded into 96-well
plates in 200 ll of medium 24 h prior to treatment with retinoids.
After 72 h of treatment with retinoids, the cells were fixed by 60 ll
of cold TCA (10% (w/v)) for 60 min at 4 C. Then 100 ll 0.4% SRB
solution was applied and the cells were incubated for 10 min at
room temperature. Unbound dye was washed five times with 1%
acetic acid and air dried. An SRB dye solubilized by 10 mM Tris-
Base solution and absorbance were acquired at 515 nm. Absor-
bance values of DMSO only treated wells, which were controls,
were used for normalization. 50% growth-inhibitory concentration
(IC50) values were calculated as described in [28].
2.4. Senescence-associated b-galactosidase (SABG) assay
T47D cells were seeded onto coverslips in 12-well plates as
7500 cells/well. After 24 h compound 17 was added to the wells
as at IC50 (3.7 lM) and IC100 (7.4 lM) levels. Control wells were
treated with only DMEM or same drug level of DMSO. Every 48 h
cell culture medium and the drug was replenished. Experiments
were stopped at 2th, 4th and 6th days of treatment and then SABG
assay was performed. Experiments were generated as a triplicate
for each condition [29]. Cells were counterstained with nuclear fast
red following SABG staining. SABG positive and negative cells from
each condition were counted under the light microscope from ran-
domly selected areas and percentages were calculated for SABG
positive and negative cells.
2.5. Western blot analyzes
Upon treatment with compound 17, cell pellets were incubated
in an NP-40 lysis buffer (50 mM Tris–HCl, pH 8.0, 250 mM NaCl,
0.1% Nonidet P-40) and a protease-inhibitor cocktail (Roche) for
30 min at 4 C. Bradford assay was performed to quantify the pro-
tein concentration of the cell lysates. 30 lg of protein was dena-
tured and resolved by SDS–PAGE using 10% gel. Then the
proteins were transferred to the nitrocellulose membranes. Mem-
branes were treated for 1 h with blocking solution (TRIS-buffered
saline containing 0.1% Tween-20 and 5% non-fat milk powder
(TBS-T)) and probed with a primary antibody for 1 h. Next, mem-
branes were washed three times with TBS-T and incubated with
an HRP-conjugated secondary antibody for 1 h. Then immune com-
plexes were detected by an ECL-plus (Amersham) kit. Calnexin and
Actin were used for equal loading control. The following antibodies
were used in this study: anti-p21Cip1 (OP64; Calbiochem), Rb (BD
Bioscience, 554136), phospho-Rb (Ser 807/811) (Cell Signaling,
9308S), Calnexin (Sigma, C4731) and Actin (Santa Cruz, sc1616).
2.6. RNA extraction, cDNA synthesis and semiquantitative RT-PCR
Total RNA was extracted from cultured cells with a Nucleo Spin
RNA II Kit (MN Macherey-Nagel, Duren, Germany) according to the
manufacturer’s protocol. Twomicrograms of total RNAwere reverse
transcribed into cDNA in a total volume of 20 ll using a Revert Aid
First Strand cDNA synthesis kit (MBI Fermentas, Vilnius, Lithuania).
The PCR reactions were carried out with 1 ll of cDNA, using the
appropriate number of cycles and annealing temperature (Tm).
Annealing temperatures (Tm) and cycle numbers were optimized
for each transcript. The PCR conditions were: RAR-a; Tm: 55 C, 30
cycles, RAR-b; Tm: 60 C, 30 cycles, RAR-c; Tm: 60 C, 32 cycles,
RXRa and RXRb; Tm: 58 C, 30 cycles, RXRc; Tm: 62 C, 35 cycles.
The primer sequences were: RAR-a F-50GAGCCGGTCCTTTGGT
CAA30, R-50CTGCGAGCATCACAGGACAT30, RAR-b F-50ATTCCAGTGC
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c F-50TACCACTATGGGGTCAGC30, R-50CCGGTCATTTCGCACAGCT30
RXRa, F-50TTCGCTAAGCTCTTGCTC30, R-50ATAAGGAAGGTGTCAAT
GGG30 RXRb, F-50GAAGCTCAGGCAAACACTAC30, R-50TGCAGTCTTT
GTTGTCCC30 RXRc, F-50GCAGTTCAGAGGACATCAAGCC30 and
R-50GCCTCACTCTCAGCTCGCTCTC-30. PCR products were analyzed
on a 2% agarose gel and visualized with ethidium bromide under
UV transillumination. The mRNA bands were quantified by the
Image J program (http://imagej.nih.gov).
2.7. siRNA transfection
siRXRa (Dharmacon) and siRXRc (Invitrogen) were transfected
into MCF7 cells by using the ‘‘reverse transfection” method accord-
ing to the manufacturer’s guidelines. siRNA silencing was then con-
firmed by RT-PCR semiquantitative RT-PCR analysis.
2.8. Statistical analysis
Statistical analysis was carried out with StatPlus:mac software
(AnalystSoft). Statistical differences between two groups were
determined using the student’s t test, and between all groups were
determined with an analysis of variance (ANOVA) test with a Bon-
ferroni adjustment. p values of <0.05 or p < 0.01 were accepted as
statistically significant.
2.9. Static docking
The coordinate files of the human retinoic acid receptors RXRc
and RXRa ligand-binding domains (pdb ID: 2GL8 and 1FBY) were
prepared for docking with the UCSF Chimera tool, a visualization
system for exploratory research and analysis [30]. The Chimera
Dock Prep tool was used to delete water molecules, to add hydro-
gen and to write the file in Mol2 format from the homotetramer
RXRc structure. A 3D structure of compound 17 was prepared in
Mol2 format with Marvin Sketch (http://www.chemaxon.com)
and the retinoic acid structure was acquired from Protein Data
Bank (pdb ligand ID: REA). Docking between RXRs and compound
17 was performed on the SwissDock server based on EADock DSS
[31,32]. Binding modes were analyzed using the Chimera tool;
the docked 2GL8 for RXRc and 1FBY for RXRa are shown in
Fig. 5.3. Results
3.1. Cytotoxic activity of retinoids in cancer cells
Twenty-seven newly synthesized retinoid derivatives [26],
N-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene-2-yl)-car-
boxamides (6-15) and 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaph-
thalene-2-carboxamides (16-32) were screened for their cytotoxic
activity in cancer cells by the SRB assay. T47D breast, Huh7 liver
and HCT116 colon cancer cells were treated with the compounds
and with ATRA, and their IC50 values were determined (Supple-
mentary Table 1 and Supplementary document 1).
The cytotoxicity induced by the compounds was prominent in
T47D cells. The compounds with the lowest IC50 concentrations
(6, 8, 10, 11, 17, 18, 24, 25, 26, and 27), were selected to be further
analyzed for their anti-proliferative activity on a larger panel of
breast cancer cells and on an MCF-12A immortalized normal breast
epithelial cell line (Table 1 and Supplementary document 2).
Compounds 6, 8, 10 and 11 have been previously synthesized as
derivatives of N-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaph-
thalene-2-yl)-carboxamides, compounds 17, 18, 24, 25, 26 and 27
have been synthesized as derivatives of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2-carboxamides [26]. Camp-
tothecin, which is a potent cytotoxic agent, was included as an
experimental positive control (Table 1).
The selected compounds had heterogeneous cytotoxic actions
on breast cancer cell lines. Compounds 17 and 24 had the lowest
IC50 values in certain cell lines (Table 1). The cytotoxicity of com-
pound 24 was more specific on BT-20 cell lines, while compound
17 exhibited broader cytotoxic activity on breast cancer cells.
The 50% growth-inhibitory concentration of compound 17 on
MCF-12A, which is the immortalized normal breast epithelial cell
line, was fivefold higher than that of T47D. Additionally, in a previ-
ous study, compound 17 was found to be non-toxic normal human
macrophage cells [26]. Therefore, compounds 17 and 24 are con-
sidered good cytotoxic agent candidates for the treatment and pre-
vention of breast cancer. Compound 17 had no cytotoxic action on
the Huh7 liver and HCT116 colon cells (Supplementary Table 1).
Based on these observations, we focused our studies on the cyto-
toxicity induced by 17, which showed the most breast-cancer-cell
specificity within the 27 tested retinoid derivatives. We also
confirmed the cytotoxic activity of retinoid 17 in phenol red free
medium in comparison with DMSO controls on T47D cells. SRB-
cytotoxicity assay was performed in triplicate and IC50 value were
identified as 9.8 lM (R2 = 0.9). When the IC50 value (3.5 lM) in the
presence of phenol red which induces mild cell proliferation, com-
pared to this value (9.8 lM), we observe that 17 may be more
active against fast proliferating cells.
3.2. Identifying the cell death type induced by 17
To understand the molecular mechanism behind the cytotoxic
effect of compound 17 (Fig. 1A), we first determined whether this
action occurs by apoptosis. To test apoptosis induction, we per-
formed in situ Hoechst-33258 staining, cytochrome C release and
PARP protein cleavage analysis (Supplementary Fig. 2) after treat-
ing T47D cells with compound 17. None of these apoptosis markers
gave positive results.
Also observed during compound 17 treatments of breast cancer
cells was a late cytotoxic response, which is indicative of long-term
cell death induction. An anti-proliferative effect was seen after
about six days of retinoid treatment. This late response led us to
consider senescence-associated cell death, which is another impor-
tant growth-inhibitory mechanism observed in cancer cells [33].
Therefore, we investigated whether senescence induction occurs
upon treating T47D cells with compound 17. SABG staining was
performed after two-, four- and six-days of treatment with 17 on
T47D cells. Compound 17 was applied to the cells at IC50
(3.7 lM) and IC100 (7.4 lM) concentrations. SABG-positive and
negative cells were counted from randomly selected areas under
the light microscope and the percentages of senescent cells were
calculated. The IC100 concentration of 17 caused statistically signif-
icant senescence associated cell death compared to DMSO controls
(Fig. 1B). Representative pictures of SABG staining are presented in
Fig. 1C. Blue cells demonstrate SABG positivity as a result of senes-
cence-associated cell death.
3.3. Molecular analysis of senescence upon 17 treatment
CDK inhibitor p21waf1/Cip1/Sid1 is an important mediator of
p53-dependent cell cycle arrest upon DNA damage [10,34]. p21
is also one of the key regulators of senescence, and ATRA treatment
causes up-regulation of p21 in different cell lines [35]. These find-
ings motivated us to determine the involvement of the p21-Rb
pathway in compound 17’s mechanism of action. For this purpose
we analyzed p21 protein levels in T47D cells treated with IC50 and
IC100 concentrations of 17 for two, four and six days. These
treatments induced a time-dependent p21 protein increase for
Table 1
Cytotoxic activities (IC50 in lM) of the retinoids on breast cancer cell lines.a
Cell lines Compounds
6 8 10 11 17 18 24 25 26 27 CPTb
CAMA-1 38.11 24.94 4.82 23.44 12.16 8.73 7.28 9.6 7.47 9.97 0.07
T47D 17.3 12.08 14.93 16.43 3.71 6.03 4.08 10.31 10.5 8.67 <0.01
MCF7 8.07 9.66 9.02 11.1 6.93 12.98 10.5 22.09 11.57 8.8 <0.01
BT474 16.52 7.81 26.35 22.01 12.91 8.37 NIc 21.38 NI 14.54 12.75
MDA-MB-453 11.97 5.9 13.6 23.33 6.19 16.92 17.48 20.57 9.03 12.33 <0.01
BT20 11.33 10.05 11.62 11.61 3.85 11.68 2.55 9.46 14.52 11.27 0.07
SK-BR-3 9.77 7.46 10.1 7.72 11.23 8.38 NI 18.68 NI 9.68 <0.01
MDA-MB-361 11.18 8.58 9.76 15.07 11.45 11.06 NI NI NI 12.15 0.14
MDA-MB-157 18.81 19.49 12.85 16.94 9.77 22.62 NI NI 14.21 7.07 0.02
MDA-MB-231 42.85 18.93 15.22 15.7 32.6 16.57 24.99 NI 13.32 12.98 <0.01
MCF-12A 17.93 NI 10.86 11.4 15.91 NI NI NI 34.62 NI <0.01
Significant IC50 are indicated in bold.
a Cytotoxicities of all 27 retinoids are given in Supplementary Table 1.
b CPT: Camptothecin is used as an experimental positive control.
c NI: no inhibition.
Fig. 1. Compound 17 leads to senescence in T47D breast cancer cells. (A) Chemical structure of compound 17. (B) T47D cells were treated with IC50 and IC100 concentrations
of 17 for 2, 4 and 6 days and subjected to an SABG assay. SABG-positive cells were counted and the percent of senescent cells was presented. (C) SABG-stained in T47D cells
upon 6 days of treatment with IC50 (3.7 lM) and IC100 (7.4 lM) concentrations of 17. p-Values were calculated by paired two-tailed t tests. *p < 0.01, **p < 0.005.
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(Fig. 2).
3.4. Correlation between retinoic acid receptors and the cytotoxicity of
17
The variation observed in the IC50 values motivated us to fur-
ther analyze the molecular mechanisms in senescence and its pos-
sible relation to RARs. Differential expressions of RAR levels in
breast cancer cells might be the reason for these cells’ diverseIC50 values obtained with the retinoid derivatives (Table 1 and
Fig. 3A). Retinoic acid and its synthetic derivatives (retinoids)
mediate their effect through RARs and RXRs. Therefore, knowledge
of RAR expression in our breast cancer cell line panel was essential
in identifying the subtype-specific cytotoxicity induced by 17. For
this purpose, the cells were characterized for their RAR and RXR
status by the semi-quantitative RT-PCR method (Fig. 3 and Supple-
mentary Fig. 3). We did not observe an association between IC50
values and RAR expression levels (Fig. 3B). Although RXRa and
RXRb were expressed equally in all cell lines tested, RXRc
Fig. 2. Senescence-associated upregulation of p21. T47D cells were treated with
compound 17 at IC50 (3.7 lM) and IC100 (7.4 lM) concentrations and in DMSO
controls. p21 protein levels were then analyzed on days 2, 4 and 6 with Western
blot. During treatment, 17 was renewed every 48 h. Calnexin was used as an equal
loading control.
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and Table 1). Indeed, this correlation could be the result of the
RXRc expression and senescent progenitor subtype described pre-
viously [22]. Therefore, we knocked down RXRa or RXRc in the
MCF7 cell line, and then treated the cells with 17. We specifically
chose MCF7 cells, which were reported to be senescent progeni-
tors, to demonstrate our hypothesis in a luminal type of breast can-
cer cell other than T47D.
3.5. Response of RXRa and RXRc knocked-down MCF7 cells to 17
MCF7 cells were transiently transfected with siRXRa, siRXRc
and scrambled siRNA as a control. The transfected cells were then
treated with compound 17 and subjected to an SRB cytotoxicity
assay (Fig. 4A). The efficiency of the knockdown was evaluated
by RT-PCR in parallel with the SRB assay (Fig. 4B and C). RT-PCR
results showed that the knockdown of RXRa was 70% achieved
and that of RXRc was silenced totally. Silencing of RXRa had no
effect on the proliferation of MCF7 cells, whereas RXRc induced
significant cytotoxic action (p < 0.02). In addition, 17was also cyto-
toxic when RXRa was knocked down. These results may suggest
that compound 17 maintained its cytotoxic effect despite the
absence of the RXRa receptor through other retinoid receptors.
(Fig. 4C).
3.6. Docking of compound 17 on RXRc
To gain more insight into the interaction between compound 17
and RXRa or RXRc at the molecular level, we performed small-
molecule docking studies with ligand-binding domains of human
retinoic acid receptors RXRa (1FBY) and RXRc (2GL8) using Swiss-
dock (Fig. 5Ai and Bi) [32]. Then we docked retinoic acid (PDB id:
REA) to RXRa and RXRc and structurally aligned it to RXRa17
and RXRc17 to demonstrate the binding site orientation of 17with
respect to REA (Fig. 5Aii and Bii). The alignment shows that
RXRc17 has more structural overlap than RXRa. This observation
further suggests that the cytotoxic effect of 17 may be due to its
interaction with RXRc and it can be further studied by molecular
dynamics studies in parallel with in vitro direct binding assays.
4. Discussion
Retinoids have been reported to be involved in chemopreven-
tion and chemotherapeutics in cancer [1,4–6]. Therefore, we exam-
ined the cytotoxic activities of newly synthesized 28 retinoids,
including ATRA, on epithelial-origin breast, liver and colon cancer
cells (Supplementary Table 1). Retinoids 6, 8, 10, 11, 17, 18, 24,
25, 26 and 27 had cytotoxic activities with IC50 values below10 lM on all cancer cell types. Retinoid 17 had selective cytotoxi-
city on T-47D breast cancer cells but not on Huh7 liver and HCT116
colon cancer cells. Regarding the importance of the hormonal com-
ponent of breast cancer, we focused on the molecular cytotoxicity
analysis of retinoid 17 for a larger panel of breast cancer cells from
different classes. We tested the cytotoxicity of retinoid derivatives
on four Luminal A (CAMA-1, T-47D, MCF-7 and MDA-MB-361), one
Luminal B (BT-474), three Triple-Negative-Basal (BT-20, MDA-MB-
157 and MDA-MB-231) and two HER2 (MDA-MB-453 and SK-BR-
3) subtypes of breast cancer cell lines (Table 1). Luminal A is the
most frequently diagnosed subtype, corresponding to 50–60% of
all breast cancers. This subgroup represents estrogen receptor pos-
itivity. Generally, the luminal subgroup of breast cancer does not
respond very well to traditional chemotherapy [36,37]; the major
treatment for this group depends on hormone therapy, such as
selective ER modulators (SERMs), like tamoxifen, and pure selec-
tive ER regulators, like fulvestrant. Another major challenge in hor-
mone-positive breast cancer is de novo or acquired resistance to
hormone therapy. Resistance to hormone therapies mostly occurs
through the activation of signaling pathways that give input to cell
cycle progression [38]. For this reason, there is a need for alterna-
tive targets and therapies for the hormone-resistant luminal group
of breast cancer as well as for other hormone-negative breast can-
cer types. On the other hand, targeted therapies for triple-negative
breast cancer (TNBC), which has a very poor prognosis and distant
recurrence, are essential. Retinoids and differential activities of
retinoid receptors in breast cancer cells have been previously stud-
ied [39]. The retinoid derivative AM580 is reported to be more
active on RARa than the pan-RAR ligand, ATRA. Furthermore, we
also do not observe significant cell growth inhibition with ATRA
(IC50 of 28.5-Supplementary Table 1) since ATRA does not bind to
RXR. Similarly, some retinoid derivatives we tested on T-47D cells
were active; some were inactive, indicating the selectivity of reti-
noids against RARs. As shown in Table 1, further cytotoxicity anal-
ysis of the most-active retinoid derivative, compound 17,
successfully blocked the proliferation of luminal and TNBC cells
at micromolar concentrations. Retinoid 17 had IC50 values of
3.71 lM for T-47D Luminal A and IC50 values of 3.88 lM for BT-
20 TNBC cells.
Our data also reveal that cell death induced by retinoid deriva-
tives is senescence in breast cancer cells. ATRA’s induction of
senescence in liver cancer cells has been previously described as
a p21-dependent mechanism for this cell death type [12]. Pan-reti-
noid ATRA or other retinoid derivatives’ modes of action in induc-
ing cell death is not clearly defined at the molecular level in breast
cancer cells [39]. On the otherhand, the T-47D cell line has been
grouped in a senescent cell progenitor (SCP) subtype and senes-
cence occurrence has been reported to be associated with estrogen
receptor loss and p21 accumulation in this cell line by our group
[14]. In correlation with these findings, we demonstrated that
compound 17 led to the accumulation of p21 and induced senes-
cence response in this cell line. In parallel, at the end of day six,
Rb levels had increased and pRb levels remained unchanged during
senescence (data not shown). In conjunction with our results, ATRA
has been shown to induce cell-cycle arrest through p21 overex-
pression in humanmonoblastic U-937 cells and liver cancer HepG2
cells, indicating the importance of retinoids in cancer therapy
[9,40]. Recently, Lim et al. showed that ATRA causes senescence
in HepG2 hepatoma cells by upregulation of p16 and p21. They
also observed RAR-b2 involvement in this effect [12]. Our study
with the retinoid derivative 17 on 11 different breast cancer cells
and a comparative analysis of RAR and RXR gene expression reveal
the importance of RXRs in breast cancer cell proliferation. RXR
knockdown experiments using RXRa- and RXRc-specific siRNAs
in the presence or absence of retinoid derivative 17 showed not
only the cell-survival-inhibitory effects of this compound but also
Fig. 3. Comparative analysis of the cytotoxic action of compound 17 and retinoid receptor expression. Dose response curves of 17 cytotoxicity with concentrations of 17 from
40 lM, 20 lM, 10 lM, 5 lM to 2.5 lM in DMSO and growth inhibitions were compared to DMSO controls (A). Experiments were done in triplicates and mean values were
indicated in the graph. Retinoic acid receptor expression levels in breast cancer cell lines (B). Breast cancer cells were lysed, mRNA was isolated and RARa, RARb, RARc, RXRa,
RXRb and RXRc levels were determined using RT-PCR. GAPDH was used for a reference gene expression.
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siRNA-mediated RXRa knockdown did not alter cell proliferation,
RXRc knockdown had a significant anti-proliferative effect on
MCF7 cells. Compound 17, had a dramatic anti-proliferative activ-
ity on RXRa knockdown cells with normal RXRc expression, indi-
cating that the major target of compound 17 can be RXRc.
However we were able to knockdown RXRa only by 70% achieved
which does not rule out that 17 does not target RXRa for its cyto-
toxic activity. Our initial docking analysis can be further investi-
gated by molecular dynamics and direct in vitro binding assays.
Similarly structurally modified two Pyrazine Arotinoid derivatives
reported to be selectively differential activities on RAR and RXRssupporting the selectivity of retinoid derivatives against retinoid
receptors [41,42]. Findings of this study showed that Retinoid X
receptors could be associated with the anti-proliferative effects
of retinoid derivative 17. We also demonstrated that RXRc expres-
sion down-regulation leads to a significant decrease in cell prolif-
eration. Therefore, we suggest that retinoid derivative 17 and
other retinoids that target RXRc, can be considered for breast can-
cer treatment in patients experiencing resistance to hormonal
therapies. We submit that mechanisms underlying the regulation
of Retinoid X receptors and small molecules’ action on these pro-
teins may merit further evaluation as a novel strategy against
breast cancer.
Fig. 4. Effect of compound 17 on RXRc- or RXRa-silenced cells. MCF-7 breast cancer cells were transiently transfected with (A) siRXRa and (B) siRXRc and scrambled siRNA,
and treated with either compound 17 or DMSO. RXR knockdown was confirmed by RT-PCR analysis. GAPDH was used for a reference gene expression. (C) Cytotoxicity of 17
was analyzed by an SRB assay. Results were analyzed by an analysis of variance (ANOVA) test. Bonferroni-adjusted p-values were indicated between groups. Each experiment
was done in triplicate.
Fig. 5. Comparative representation of compound 17 docked on RXRa and RXRc. Compound 17 was docked to the ligand-binding domains of human retinoic acid receptors:
(Ai) RXRa (PDB-ID: 1FBY) and (Bi) RXRc (PDB-ID: 2GL8). Retinoic acid docked RXRa and RXRcwere structurally aligned with (Aii) RXRa17 and (Bii) RXRc17 to demonstrate
the binding site orientation of 17 with respect to REA. RXRc had a better structural alignment than RXRa. (Ci-ii) Surface representation of RXRc with 17, where purple
indicates the most-hydrophilic and tan-color indicates the most-hydrophobic regions.
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